Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 7/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16297339 | 0.88 | CYP19A1 (0.39) | CYP19A1ITGA4ITGB7RORCPTGDR2 | |
| SCHEMBL16747636 | 0.85 | RORC (0.34) | CYP19A1ITGA4ITGB7RORCPTGDR2 | |
| SCHEMBL16747646 | 0.84 | HTR2C (0.36) | ITGA4ITGB7ALDH1A1KMT2A | |
| SCHEMBL16747615 | 0.84 | HTR2C (0.36) | ITGA4ITGB7ALDH1A1KMT2A | |
| SCHEMBL16293606 | 0.81 | ITGA4 (0.44) | CYP19A1ITGA4ITGB7PTGDR2PDE1C | |
| SCHEMBL16296538 | 0.81 | ITGA4 (0.39) | CYP19A1ITGA4ITGB7RORCPTGDR2 | |
| SCHEMBL16737740 | 0.78 | CYP19A1 (0.48) | CYP19A1ITGA4ITGB7PTGDR2PDE1C | |
| SCHEMBL16737859 | 0.78 | PTGDR2 (0.35) | CYP19A1ITGA4ITGB7RORCPTGDR2 | |
| SCHEMBL16737861 | 0.78 | PTGDR2 (0.35) | CYP19A1ITGA4ITGB7RORCPTGDR2 | |
| SCHEMBL16744666 | 0.77 | CYP19A1 (0.42) | CYP19A1ITGA4ITGB7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | CYP19A1 444/4885ITGA4 222/4885ITGB7 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.